Free Biopharma Daily Stock Updates - 05/03/21

$XBI $135 -2%

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Covid Updates

$RVVTF +6% Research agreement with UCSF for Bucillamine as potential treatment for severe Covid-19. source


$NVAX -15% Initiated pediatric expansion of Phase 3 trial of NVX-CoV2372 in patients 12-17 years. source


$EIGR +2% Peginterferon Lambda to be added to ongoing Phase 3 TOGETHER platform study in outpatients with COVID-19. source


$COCP +7% Aggressively developing novel coronavirus protease inhibitors (lead candidate CDI-45205) for prophylactic and therapeutic use; likely to be effective against new variants. source


$MRNA +4% WHO issued EUL for COVID-19 vaccine; supply agreement with Gavi to delivery vaccine to lowest income countries. source


$OCGN +29% COVAXIN effectively neutralizes Brazil variant along with UK variant and India double mutant variant. source


$VXRT -25% (+23% AH) A Phase II trial of VXA-CoV2-1 expected to start mid-year 2021 instead of 2Q; provided data comparing T-cell responses of VXA-CoV2-1 to other vaccines. source


$VXRT -25% (+23% AH) New data suggests broad cross-coronavirus activity. source


Pipeline Updates

$TARS +4% Presents updated data from ATLAS and Europa studies of TP-03 in Demodex blepharitis at ARVO 2021. source


$MRUS +9% First patient dosed in ph 1/2 trial of MCLA-129 in advanced lung cancer and other solid tumors. source


$CYDY -1% On track for rolling submission of Vyrologix BLA in July 2021. source


$CYDY -1% Preparing a request for pre Breakthrough Therapy designation meeting ahead of expected Phase 3 trial for 22 solid tumor cancer indications. source


$NOVN -7%Final patient in B-SIMPLE4 trial completed last Week-12 visit. source


$AGLE +2% Completed patient randomization for phase 3 trial of pegzilarginase. source


$XBIT +1% Reached agreement to supply XB20-01 cancer drug to INSERM. source


$OCUL -3% FDA confirmed fulfilled all post-approval study requirements for ReSure Sealant. source


$KYMR -4% Presented positive late breaking data of IRAK4 to treat patients with hidradenitis suppurativa. source


$XOMA -4% First patient dosed in Phase 3 trial evaluating cetrelimab. source


$ZEAL +1% Published results from Phase 3 trial of dasiglucagon in Diabetes Care. source


$CFRX -8% Patent office issued Patent on 4/27/21 for CF-370. source


$FOLD +5% Completed Type B pre BLA meeting for AT-GAA; intends to complete rolling BLA submission in second quarter. source


$CLSD -3% Resubmitted NDA for XIPERE to treat macular edema associated with uveitis; expect six month review timeline. source


$AVRO -19% Initiating registration trial in mid 2022 to support future full approval of AVR-RD-01. source


$AMPH +3% FDA approval for morphine sulfate injection. source


$ADVM -5% Long term data from OPTIC clinical trial of ADVM-022 reported. source


$AZN +1% Farxiga approved to treat chronic kidney disease in patients at risk of progression. source


$OBSV -6% Posters presented at ACOG on safety parameters of linzagolix. source


$OYST -4% Presentation of data analyses from its Phase 3 ONSET-2 clinical trial evaluating OC-01. source


$TXMD -5% ANNOVERA presented at 2021 ACOG meeting on menstrual bleeding profile data. source


$CABA -4% Acute safety data from the first cohort in the DesCAARTes™ trial announced today; no dose limiting toxicities. source


$KPTI +1% Seven abstracts highlighting data from solid tumor studies will be presented at the upcoming 2021 ASCO Annual Meeting taking place June 4-8, 2021. source


$CLNN +7% Patent office issued notices of allowance for two patent applications for platform technology. source



Financial Updates

$RYTM +2% First commercial sales of IMCIVREE completed in the first quarter. source


$KPTI +1% First quarter product sales of XPOVIO $21.7M. source



0 comments